Cargando…
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
BACKGROUND: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to ach...
Autores principales: | Adams, Richard A, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Madi, Ayman, Fisher, David, Kenny, Sarah L, Kay, Edward, Hodgkinson, Elizabeth, Pope, Malcolm, Rogers, Penny, Wasan, Harpreet, Falk, Stephen, Gollins, Simon, Hickish, Tamas, Bessell, Eric M, Propper, David, Kennedy, M John, Kaplan, Richard, Maughan, Timothy S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lancet Pub. Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159416/ https://www.ncbi.nlm.nih.gov/pubmed/21641867 http://dx.doi.org/10.1016/S1470-2045(11)70102-4 |
Ejemplares similares
-
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009) -
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012) -
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
por: Maughan, Timothy S, et al.
Publicado: (2011) -
Nonadaptive Amino Acid Convergence Rates Decrease over Time
por: Goldstein, Richard A., et al.
Publicado: (2015) -
Phenoscape: Identifying Candidate Genes for Evolutionary Phenotypes
por: Edmunds, Richard C., et al.
Publicado: (2016)